Strategies for fertility preservation in young early breast cancer patients.

[1]  P. Bruzzi,et al.  Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. , 2014, Cancer treatment reviews.

[2]  R. Tamimi,et al.  Prospective study of fertility concerns and preservation strategies in young women with breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Puglisi,et al.  Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. , 2014, Endocrine-related cancer.

[4]  N. Pavlidis,et al.  Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Oktay,et al.  Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Fu,et al.  Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis , 2013, PloS one.

[7]  M. Lambertini,et al.  Fertility counseling of young breast cancer patients. , 2013, Journal of thoracic disease.

[8]  H. Kanety,et al.  Cyclophosphamide Triggers Follicle Activation and “Burnout”; AS101 Prevents Follicle Loss and Preserves Fertility , 2013, Science Translational Medicine.

[9]  E. Ginsburg,et al.  Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. , 2013, Fertility and sterility.

[10]  Xiao-yan Li,et al.  Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. , 2013, Breast.

[11]  O. Khorshid,et al.  Gonadatrophin Suppression to Prevent Chemotherapy-Induced Ovarian Damage: A Randomized Controlled Trial , 2013, Obstetrics and gynecology.

[12]  Pietro Panizza,et al.  The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. , 2012, European journal of cancer.

[13]  J. Donnez,et al.  Live birth after transplantation of frozen-thawed ovarian tissue after bilateral oophorectomy for benign disease. , 2012, Fertility and sterility.

[14]  P. Dieppe,et al.  Failure rates of stemmed metal-on-metal hip replacements – Authors' reply , 2012, The Lancet.

[15]  L. Rienzi,et al.  Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. , 2012, Human reproduction.

[16]  O. Pagani,et al.  Pregnancy after Breast Cancer: Myths and Facts , 2012, Breast Care.

[17]  Z. Rosenwaks,et al.  Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer , 2012, Journal of Assisted Reproduction and Genetics.

[18]  S. S. Kim,et al.  Fertility considerations in young women with hematological malignancies , 2012, Journal of Assisted Reproduction and Genetics.

[19]  A. Borini,et al.  Oocyte slow freezing using a 0.2-0.3 M sucrose concentration protocol: is it really the time to trash the cryopreservation machine? , 2012, Fertility and sterility.

[20]  J. Litton.  Breast Cancer and Fertility , 2012, Current Treatment Options in Oncology.

[21]  P. Munster,et al.  Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Sotiriou,et al.  Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling , 2012, Clinical Cancer Research.

[23]  F. Peccatori,et al.  Multiple Approaches for Individualized Fertility Protective Therapy in Cancer Patients , 2011, Obstetrics and gynecology international.

[24]  Li'na Hu,et al.  Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. , 2011, The Cochrane database of systematic reviews.

[25]  Ahmedin Jemal,et al.  Breast cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[26]  L. Boni,et al.  Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. , 2011, JAMA.

[27]  K. Snyder,et al.  Discussing fertility preservation options with patients with cancer. , 2011, JAMA.

[28]  J. Donnez,et al.  Preservation of fertility in females with haematological malignancy , 2011, British journal of haematology.

[29]  M. Rezai,et al.  Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Iwase,et al.  Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane , 2011, Breast cancer.

[31]  M. Piccart,et al.  Motherhood after breast cancer: searching for la dolce vita , 2011, Expert review of anticancer therapy.

[32]  L. Del Mastro,et al.  Medical approaches to preservation of fertility in female cancer patients , 2011, Expert opinion on pharmacotherapy.

[33]  S. Kim,et al.  Use of Hormonal Protection for Chemotherapy-induced Gonadotoxicity , 2010, Clinical obstetrics and gynecology.

[34]  L. Kjeldsen,et al.  Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. , 2010, Fertility and sterility.

[35]  A. Luini,et al.  Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  N. Desai,et al.  Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. , 2010, Fertility and sterility.

[37]  R. Stouffer,et al.  Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation. , 2010, Human reproduction update.

[38]  Y. Englert,et al.  Birth of a second healthy girl more than 3 years after cryopreserved ovarian graft. , 2010, Human reproduction.

[39]  K. Schmidt,et al.  Risk of ovarian failure and fertility preserving methods in girls and adolescents with a malignant disease , 2010, BJOG : an international journal of obstetrics and gynaecology.

[40]  L. Holmberg,et al.  Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment , 2009, PloS one.

[41]  A. Rosen,et al.  Psychosocial distress in young cancer survivors. , 2009, Seminars in oncology nursing.

[42]  R. Chian,et al.  Fertility Preservation with Immature and in Vitro Matured Oocytes , 2009, Seminars in reproductive medicine.

[43]  P. Neven,et al.  Reproduction rates after cytotoxic therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  B. Hamilton,et al.  Delayed childbearing: more women are having their first child later in life. , 2009, NCHS data brief.

[45]  M. El-ashry,et al.  Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. , 2009, Fertility and sterility.

[46]  T. Fornander,et al.  Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial , 2009, Breast Cancer Research and Treatment.

[47]  J. Visser,et al.  Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. , 2008, Human reproduction.

[48]  D. Baird,et al.  Ovarian cryopreservation for fertility preservation: indications and outcomes. , 2008, Reproduction.

[49]  T. Gurgan,et al.  Pregnancy and assisted reproduction techniques in men and women after cancer treatment. , 2008, Placenta.

[50]  M. Dowsett,et al.  Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC) , 2008, Breast Cancer Research and Treatment.

[51]  H. Chang,et al.  Fertility preservation for women with malignancies: current developments of cryopreservation. , 2008, Journal of gynecologic oncology.

[52]  K. Oktay,et al.  Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  K. Oktay,et al.  Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function , 2007, Cancer.

[54]  Z. Blumenfeld.  How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. , 2007, The oncologist.

[55]  E. Schiff,et al.  Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. , 2007, Human reproduction.

[56]  I. Cohen,et al.  Fertility Preservation Options for Women With Malignancies , 2007, Obstetrical & gynecological survey.

[57]  M. Venturini,et al.  Infertility and pregnancy after breast cancer: current knowledge and future perspectives. , 2006, Cancer treatment reviews.

[58]  J. Donnez,et al.  Ovarian tissue cryopreservation and transplantation: a review. , 2006, Human reproduction update.

[59]  P. Patrizio,et al.  American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  A. Blasio,et al.  Gonadotropin‐releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma , 2006, Cancer.

[61]  K. Oktay.  Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Bernard,et al.  Livebirth after cryopreserved ovarian tissue transplantation , 2004, The Lancet.

[63]  Z. Rosenwaks,et al.  Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation , 2004 .

[64]  Terry L. Smith,et al.  Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence , 2004, Cancer.

[65]  K. Schmiegelow,et al.  Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. , 2003, The Journal of clinical endocrinology and metabolism.

[66]  E. Lawrence,et al.  Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. , 1995, Biology of reproduction.

[67]  R. Sankila,et al.  Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect". , 1994, American journal of obstetrics and gynecology.

[68]  M. Faddy,et al.  Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. , 1992, Human reproduction.

[69]  B. Szende,et al.  Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. , 1990, British Journal of Cancer.

[70]  S. Rivkees,et al.  The relationship of gonadal activity and chemotherapy-induced gonadal damage. , 1988, JAMA.

[71]  W. LeMaire,et al.  A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. , 1985, Cancer research.

[72]  K. Kovacs,et al.  Metastatic cancer of the pituitary gland. , 1973, Oncology.

[73]  M. Piccart,et al.  Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  I. Smith,et al.  Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  P. Munster.  Fertility preservation and breast cancer: A complex problem. , 2013, Oncology.

[76]  Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. , 2019, Fertility and sterility.

[77]  J. Litton,et al.  Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies , 2011 .

[78]  E. De Ponti,et al.  Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study. , 2009, Reproductive biomedicine online.

[79]  L. Boni,et al.  Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  J. Visser,et al.  Anti-Müllerian hormone: a new marker for ovarian function. , 2006, Reproduction.

[81]  Z. Rosenwaks,et al.  Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. , 2003, Human Reproduction.